TCRR

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

By Dana Blankenhorn, InvestorPlace Contributor
A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors.

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC

By Bret Kenwell, InvestorPlace Contributor
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.